Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Wanli Ge

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112210438. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 19

  1. Machine learning-based integration develops a lactate metabolism related gene signature for improving outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.seminoncol.2025.152428↗
  2. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  3. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-025-07740-8↗
  4. MiR-548t-5p regulates pancreatic ductal adenocarcinoma metastasis through an IL-33-dependent crosstalk between cancer cells and M2 macrophages. First author DOI 10.1080/15384101.2024.2309026↗
  5. The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer. Co-author DOI 10.1155/2023/6891636↗
  6. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  7. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  8. Suppressive effect of YY1-mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma. First author DOI 10.3892/ol.2022.13577↗
  9. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Co-author DOI 10.1038/s41388-021-01741-5↗
  10. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Co-author DOI 10.1155/2021/6530298↗
  11. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  12. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  13. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  14. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-020-2475-3↗
  15. Optimization of internal reference genes for qPCR in human pancreatic cancer research. Co-author DOI 10.21037/tcr.2020.02.48↗
  16. LncRNA KCNK15-AS1 inhibits pancreatic cancer progression by promoting the expression of its binding protein ACTR3B Co-author DOI 10.21203/rs.3.rs-55282/v1↗
  17. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  18. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗
  19. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Co-author DOI 10.2147/ott.s157759↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 15 shared papers, 2018–2025 · strength 2.03
  2. Lingdong Meng · 13 shared papers, 2019–2025 · strength 1.78
  3. Qun Chen · 13 shared papers, 2019–2025 · strength 1.68
  4. Peng Shen · 11 shared papers, 2019–2025 · strength 1.45
  5. Xumin Huang · 11 shared papers, 2019–2025 · strength 1.40
  6. Yi Miao · 12 shared papers, 2018–2022 · strength 1.34
  7. Hao Yuan · 9 shared papers, 2018–2025 · strength 1.08
  8. Guodong Shi · 8 shared papers, 2018–2025 · strength 0.98
  9. Jingjing Zhang · 7 shared papers, 2019–2024 · strength 0.93
  10. Shouji Cao · 5 shared papers, 2020–2023 · strength 0.70
  11. Lei Chen · 5 shared papers, 2018–2025 · strength 0.60
  12. Yi Miao · 3 shared papers, 2022–2025 · strength 0.60
  13. Taoyue Yang · 4 shared papers, 2021–2022 · strength 0.50
  14. Pengfei Wu · 4 shared papers, 2020–2022 · strength 0.45
  15. Yun-Peng Peng · 1 shared paper, 2026 · strength 0.36
  16. Huijuan Li · 1 shared paper, 2026 · strength 0.36
  17. Zipeng Lu · 3 shared papers, 2020–2022 · strength 0.35
  18. Pengfei Wu · 2 shared papers, 2021–2022 · strength 0.26
  19. Qun Chen · 2 shared papers, 2018–2022 · strength 0.25
  20. Min Tu · 2 shared papers, 2020–2022 · strength 0.23
  21. Xiong-Fei Zhang · 1 shared paper, 2024 · strength 0.23
  22. Yan Wang · 1 shared paper, 2024 · strength 0.23
  23. Kuirong Jiang · 2 shared papers, 2020 · strength 0.20
  24. Xiaole Zhu · 1 shared paper, 2023 · strength 0.18
  25. Qiang Li · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.